Investors Buy Large Volume of Call Options on Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was the target of some unusual options trading on Tuesday. Stock investors bought 724 call options on the company. This is an increase of approximately 892% compared to the average volume of 73 call options.

Shares of NASDAQ:RARE opened at $41.56 on Wednesday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -5.62 and a beta of 2.16. The business has a 50 day moving average price of $39.77 and a 200 day moving average price of $51.22. The company has a quick ratio of 6.64, a current ratio of 6.79 and a debt-to-equity ratio of 0.04. Ultragenyx Pharmaceutical has a twelve month low of $35.41 and a twelve month high of $74.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. The business had revenue of $25.80 million during the quarter, compared to the consensus estimate of $28.88 million. During the same period in the prior year, the firm earned ($1.74) earnings per share. The business’s quarterly revenue was up 119.4% on a year-over-year basis. Analysts anticipate that Ultragenyx Pharmaceutical will post -7.28 EPS for the current year.

A number of brokerages have issued reports on RARE. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Cowen reissued a “buy” rating and issued a $62.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 5th. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Wedbush reaffirmed a “buy” rating and set a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, August 15th. Finally, Leerink Swann reaffirmed a “positive” rating and set a $85.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $73.33.

In related news, CEO Emil D. Kakkis acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average cost of $43.63 per share, with a total value of $218,150.00. Following the purchase, the chief executive officer now owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Rothschild & Co. Asset Management US Inc. increased its position in Ultragenyx Pharmaceutical by 89.5% during the second quarter. Rothschild & Co. Asset Management US Inc. now owns 105,275 shares of the biopharmaceutical company’s stock worth $6,685,000 after acquiring an additional 49,735 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 12.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,511 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 515 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Ultragenyx Pharmaceutical by 6.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 212 shares during the period. Aperio Group LLC raised its position in shares of Ultragenyx Pharmaceutical by 21.4% during the second quarter. Aperio Group LLC now owns 9,130 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 1,608 shares during the last quarter. Finally, Sector Gamma AS raised its position in shares of Ultragenyx Pharmaceutical by 20.8% during the second quarter. Sector Gamma AS now owns 79,653 shares of the biopharmaceutical company’s stock valued at $5,058,000 after buying an additional 13,718 shares during the last quarter.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Story: How to invest using market indexes

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit